Arca
Skip to content
Tools
Tools

TOP2A, TOP2B: DNA topoisomerase II

Family in Homo sapiens that 9 drugs act on.

  • Drugs that act on it: 9
  • Approved: 4
  • In phases 1 to 3: 5
  • Sponsors: 7

Who is on it, and how far along

Every drug ChEMBL records acting on TOP2A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 9

Approved4

  • Etoposide
  • Dexrazoxane
  • Teniposide
  • Amsacrine

Phase 33

  • Vosaroxin
  • Becatecarin
  • Pazufloxacin

Phase 22

  • Berubicin
  • C-1311

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Laboratorios Sophia S.A de C.V.111%
    • Sunesis Pharmaceuticals111%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: DNA topoisomerase II inhibitor.
    EtoposideApprovedGSKSmall moleculeInhibitor494
    DexrazoxaneApprovedPfizerSmall moleculeInhibitor18
    TeniposideBoxed warningApprovedHQ Specialty PharmaSmall moleculeInhibitor7
    AmsacrineApproved—Small moleculeInhibitor2
    VosaroxinPhase 3Sunesis PharmaceuticalsSmall moleculeInhibitor1
    BecatecarinPhase 3Helsinn HealthcareSmall moleculeInhibitor0
    PazufloxacinPhase 3Laboratorios Sophia S.A de C.V.Small moleculeInhibitor0
    BerubicinPhase 2CNS PharmaceuticalsSmall moleculeInhibitor1
    C-1311Phase 2—Small moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 27 in all, from ClinicalTrials.gov.
    A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)EtoposidePhase 3Not yet recruitingGlaxoSmithKlineNov 18, 2026
    Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung CancerEtoposideNot applicableNot yet recruitingLI FENGNov 10, 2026
    Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute LeukemiaEtoposidePhase 2Enrolling by invitationGuangdong Second Provincial General HospitalNov 6, 2026
    Allogeneic Cell Therapy in Refractory T-Cell LymphomaEtoposidePhase 2Not yet recruitingUniversity Medical Center GoettingenNov 5, 2026
    A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression-Free Survival in Limited-Stage Small Cell Lung CancerEtoposidePhase 2 / Phase 3Not yet recruitingLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNov 5, 2026
    Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaEtoposidePhase 2Not yet recruitingSt. Jude Children's Research HospitalNov 4, 2026
    Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung CancerEtoposidePhase 2Not yet recruitingTianjin Medical University Cancer Institute and HospitalNov 2, 2026
    A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region UnmethylatedTeniposideNot applicableNot yet recruitingSun Yat-sen UniversityOct 26, 2026
    Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerEtoposideEarly phase 1RecruitingOliver JonasOct 23, 2026
    The CARDIOPROTECT TrialDexrazoxanePhase 2Not yet recruitingBeth Israel Deaconess Medical CenterJun 17, 2026
    Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled StudyTeniposidePhase 2RecruitingSun Yat-sen UniversityMay 13, 2026
    Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.TeniposidePhase 2RecruitingChengcheng GuoSep 23, 2025
    Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSLTeniposidePhase 2 / Phase 3RecruitingHuashan HospitalSep 22, 2025
    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic LeiomyosarcomaDexrazoxanePhase 2RecruitingUniversity of Colorado, DenverAug 15, 2025
    Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSLTeniposideNot applicableRecruitingThe First Affiliated Hospital of Soochow UniversityJul 20, 2025
    Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung CancerTeniposidePhase 2RecruitingShanghai Pulmonary Hospital, Shanghai, ChinaJan 6, 2025
    IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.AmsacrinePhase 3RecruitingIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSDec 3, 2024
    Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSTeniposidePhase 2Not yet recruitingPeking University Shenzhen HospitalNov 18, 2024
    Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary BlastomaDexrazoxanePhase 3RecruitingChildren's Oncology GroupOct 18, 2024
    CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML PatientsDexrazoxanePhase 2RecruitingPrincess Maxima Center for Pediatric OncologyFeb 16, 2024
    Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaDexrazoxanePhase 3RecruitingStichting Hemato-Oncologie voor Volwassenen NederlandJan 23, 2024
    Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLAmsacrinePhase 1 / Phase 2RecruitingHeinrich-Heine University, DuesseldorfApr 11, 2023
    Venetoclax Basket Trial for High Risk Hematologic MalignanciesDexrazoxanePhase 1Active, not recruitingAndrew E. Place, MDMar 23, 2022
    A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma MultiformeBerubicinPhase 2Active, not recruitingCNS Pharmaceuticals, Inc.Feb 21, 2021
    A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT StrategyDexrazoxanePhase 3RecruitingShanghai Children's Medical CenterJul 20, 2020
    A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsDexrazoxanePhase 3RecruitingChildren's Oncology GroupMar 3, 2020
    Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CRVosaroxinPhase 2 / Phase 3RecruitingUniversity Hospital, AngersApr 15, 2015

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2094255, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.